NCT02186509View on ClinicalTrials.gov

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 30, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

December 31, 2018

Conditions
Adult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic OligodendrogliomaAdult Brain Stem GliomaAdult Diffuse AstrocytomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Mixed GliomaAdult OligodendrogliomaAdult Pilocytic AstrocytomaAdult Pineal Gland AstrocytomaAdult Subependymal Giant Cell AstrocytomaRecurrent Adult Brain Tumor
Interventions
RADIATION

Hyperfractionated radiation therapy

Undergo hyperfractionated radiation therapy

RADIATION

Stereotactic radiosurgery

Undergo stereotactic radiosurgery

DRUG

Alisertib

Given PO

PROCEDURE

Quality-of-life assessment

Ancillary studies

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER